Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 1;14(2):964–977. doi: 10.1002/jcsm.13178

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Comparison of inflammatory, degenerative and mitochondrial parameters among controls (CTLs), IBM patients with stable evolution (stable IBM) and IBM patients with disease progression (progressive IBM). Ratios between IBM (stable or progressive) and control fibroblasts were measured to compare inflammatory, degenerative and mitochondrial parameters among the three groups (Table S8). Briefly, stable IBM showed an increased pro‐inflammatory and organic acids signature compared with progressive IBM and controls. Progressive IBM showed increased oxidative stress (ROS) and antioxidant capacity. Together, IBM stable and progressive present an evident decrease in LC3BII time‐course (autophagy marker) and COX/CS (cytochrome c oxidase related to citrate synthase, a marker of mitochondrial mass) with respect to CTLs (ratio > 1: Higher concentration in IBM; ratio < 1: Lower concentration in IBM).